Sera Prognostics (NASDAQ:SERA) Stock: Insider Tiffany Eul Davis Inglis Sells 8,024 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) insider Tiffany Eul Davis Inglis sold 8,024 shares of Sera Prognostics stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $2.03, for a total value of $16,288.72. Following the sale, the insider directly owned 83,565 shares in the company, valued at approximately $169,636.95. The trade was a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tiffany Eul Davis Inglis also recently made the following trade(s):

• On Thursday, September 10th, Tiffany Eul Davis Inglis sold 486 shares of Sera Prognostics stock. The stock was sold at an average price of $2.00, for a total value of $972.00.

Sera Prognostics Stock Performance

SERA stock opened at $2.07 on Thursday. Sera Prognostics, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $3.95. The company has a market capitalization of $81.66 million, a price-to-earnings ratio of -3.09 and a beta of 1.06. The business’s 50 day moving average price is $2.05 and its two-hundred day moving average price is $2.02.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sell-side analysts forecast that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds have recently bought and sold shares of SERA. Sanders Morris Harris LLC purchased a new stake in Sera Prognostics in the third quarter worth about $642,000. AWM Investment Company Inc. bought a new position in shares of Sera Prognostics during the second quarter valued at approximately $377,000. Segall Bryant & Hamill LLC purchased a new position in shares of Sera Prognostics during the first quarter valued at approximately $193,000. Finally, Arkadios Wealth Advisors purchased a new position in shares of Sera Prognostics during the first quarter valued at approximately $25,000. Institutional investors own 54.64% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Sera Prognostics has an average rating of “Moderate Buy” and a consensus price target of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company develops and commercializes blood tests designed to identify women at elevated risk for pregnancy complications, particularly spontaneous preterm birth.

Its lead product, the PreTRM Test, is a blood-based test that analyzes proteins associated with pregnancy and provides an individualized risk assessment for spontaneous preterm birth in singleton pregnancies.